MedTrace Logo

Spironolactone Against Anthracycline-induced Cardiomyopathy

NCT02053974 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2014-02-04

No results posted yet for this study

Summary

This study sought to investigate the whether spironolactone protects the heart against anthracycline-induced cardiotoxicity.

Conditions

  • Anthracycline Induced Cardiotoxicity

Interventions

DRUG

Spironolactone

Spironolactone

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • TC Erciyes University

    lead OTHER

Principal Investigators

  • Mahmut Akpek, M.D. · Erciyes University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02053974 on ClinicalTrials.gov